Equities research analysts predict that Jounce Therapeutics, Inc. (NASDAQ:JNCE) will post sales of $20.00 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Jounce Therapeutics’ earnings. The firm is scheduled to announce its next quarterly earnings results on Wednesday, November 8th.

On average, analysts expect that Jounce Therapeutics will report full year sales of $20.00 million for the current year, with estimates ranging from $80.58 million to $81.00 million. For the next year, analysts anticipate that the business will post sales of $129.86 million per share, with estimates ranging from $80.58 million to $206.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Jounce Therapeutics.

Jounce Therapeutics (NASDAQ:JNCE) last posted its quarterly earnings results on Wednesday, August 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.04. The business had revenue of $20.29 million during the quarter, compared to analyst estimates of $19.94 million. During the same period in the previous year, the business posted ($7.23) EPS.

JNCE has been the topic of a number of research analyst reports. Cowen and Company reaffirmed a “buy” rating on shares of Jounce Therapeutics in a report on Friday, June 9th. Zacks Investment Research downgraded Jounce Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $23.67.

Shares of Jounce Therapeutics (JNCE) traded down 1.11% during trading on Friday, reaching $15.15. The company’s stock had a trading volume of 269,302 shares. The stock’s 50 day moving average is $13.86 and its 200 day moving average is $19.04. The firm has a market cap of $487.13 million and a P/E ratio of 561.11. Jounce Therapeutics has a one year low of $11.05 and a one year high of $29.29.

A number of hedge funds have recently bought and sold shares of JNCE. American Century Companies Inc. bought a new position in Jounce Therapeutics in the first quarter valued at about $767,000. Bank of New York Mellon Corp bought a new position in Jounce Therapeutics in the first quarter valued at about $385,000. UBS Asset Management Americas Inc. bought a new position in Jounce Therapeutics in the first quarter valued at about $2,761,000. Ameriprise Financial Inc. bought a new position in Jounce Therapeutics in the first quarter valued at about $3,550,000. Finally, Omega Fund Management LLC bought a new position in Jounce Therapeutics in the first quarter valued at about $12,747,000. 43.50% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/09/09/analysts-anticipate-jounce-therapeutics-inc-jnce-will-post-quarterly-sales-of-20-00-million.html.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.

Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.